Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Kailera reports Q2 2026 results, oral IND active, Phase 2b fully enrolledAug 12Quarterly updateKailera Therapeutics, Inc.